https://cosmosscholars.com/phms/index.php/wjor <strong>World Journal of Oncology Research</strong> is a peer-reviewed scientific journal which strengthens the research and educational base of Oncology. The journal provides an active platform for epidemiologists, medical oncologists, radiation oncologists, radiologists, pathologists and researchers all over the world to promote, share, and discuss original scientific latest and outstanding research articles concerned with basic and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. Cosmos Schoalrs Publishing House en-US World J. of Oncology Research 2413-7308 <h4>Policy for Journals/Articles with Open Access</h4>Authors who publish with this journal agree to the following terms:<br /><ol type="a"><ol type="a"><li>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a <a href="http://creativecommons.org/licenses/by/3.0/" target="_new">Creative Commons Attribution License</a> that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li></ol></ol><br /><ol type="a"><li>Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work</li></ol><h4>Policy for Journals / Manuscript with Paid Access</h4>Authors who publish with this journal agree to the following terms:<br /><ol type="a"><ol type="a"><li>Publisher retain copyright .</li></ol></ol><br /><ol type="a"><li>Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .</li></ol> https://cosmosscholars.com/phms/index.php/wjor/article/view/887 <p class="04-abstract"><em>Purpose: </em>Transcriptional enhancer factor 1-related (RTEF-1) also known as TEAD4 is expressed in ocular vascular endothelial cells and plays a role in the control of VEGF expression. Alternative processing of TEAD4 hnRNA results in different proteins able to stimulate or inhibit VEGF gene transcription. The purpose of this study is to test whether short peptide fragments (STY-RMR), representing functional domains of the inhibitory TEAD4₂₁₆ isoform, can inhibit tumor as well as endothelial cell proliferation.</p><p class="04-abstract"><em>Experimental Design: </em>Cell proliferation was assessed using a colorimetric assay in cell lines incubated with STY-RMR, the amount of secreted VEGF within media was determined both in treated and control cell lines.</p><p class="04-abstract"><em>Results: </em>Significant dose dependent inhibition of cell proliferation was observed. Maximal inhibition of ocular melanoma (Mel 202 and Mel 207) cell proliferation was observed at a dose of 30 mg/100ml of STY-RMR (87% and 60% inhibition, respectively). At the same dose, more than 50% inhibition was observed in retinoblastoma and breast cancer cells (P &lt;0.001). Significant inhibition of primate ocular endothelial cell proliferation (42% at 30 mg/100 ml (p &lt; 0.001), and retinal pigment epithelial cells showed also a 75% inhibition (p = 0.007). Secreted VEGF was decreased in the media of all tested cell lines that had been exposed to STY-RMR.</p><p class="04-abstract"><em>Conclusion: </em>Functional short peptide domains derived from the TEAD4₂₁₆isoform may prove to be useful for treatment of ocular tumors and other VEGF dependent neovascular disease.</p><p class="04-abstract">Inhibition of proliferation and VEGF production within ocular endothelial cells indicate the potential of this agent to treat age-related macular degeneration (ARMD) and diabetic retinopathy (DR).</p> Bissan Ahmed Andrew Stempel Trevor J. McFarland Bruce Ksander Binoy Appukuttan Tim Stout Copyright (c) 2018-10-31 2018-10-31 5 1 9